System.Linq.Enumerable+WhereEnumerableIterator`1[Umbraco.Core.Models.IPublishedContent]30
HeadlineItem:8+ million CoolSculpting® treatments worldwide and counting.
summary:<p>It’s no secret why CoolSculpting is the #1 nonsurgical fat reduction treatment.* CoolSculpting is the only FDA-cleared cryolipolysis technology and is a proven safe and effective way to destroy fat in <strong><a href="#isi_indications" class="isi-floating-expand" onclick="setCookie('isi_clicked', 'yes', 3600)"><span style="color: #46a7dc;">9 areas of the body.</span></a></strong></p> <p>And the US market for noninvasive fat reduction continues to grow.<sup>2,†</sup> Learn how CoolSculpting can help take your practice further.</p>
ctaLabel:Discover
ctaLink:/coolsculpting/
Summary Disclaimer:<p>*CoolSculpting is the treatment doctors use most for noninvasive fat removal.   |     <sup><span>†</span></sup>Over 75 million people in the US would consider noninvasive fat reduction treatments. Results from a survey of consumers ages 18 to 75 years with a BMI of 18.5 to 34.9 and an annual household income of $35,000 or more. US population, age, and income data from 2018 US census projections.</p>
Before CoolTone treatment.
Image Disclaimer:<p>Patient was treated with CoolSculpting® on her abdomen. Results may vary.</p>
1
HeadlineItem:CoolTone™: Allergan’s latest innovation in body contouring.
summary:<p>Expand your patient offerings with muscle stimulation. CoolTone’s Magnetic Muscle Stimulation (MMS) strengthens, tones, and firms the muscles of the abdomen, buttocks, and thighs.</p> <p>CoolTone has 50% more magnetic intensity than the leading competitor, measured in tesla at the point of patient contact.<sup><span>‡</span></sup></p>
ctaLabel:Discover
ctaLink:/about/
Summary Disclaimer:<p><!--(figmeta)eyJmaWxlS2V5IjoiN1NnUml2UEM2amtaZU1PV0RPNWdrTSIsInBhc3RlSUQiOjY2Nzk5NDUyOCwiZGF0YVR5cGUiOiJzY2VuZSJ9Cg==(/figmeta)--><!--(figma)ZmlnLWtpd2kBAAAA6xoAALVa958jSXWvamnSzqYLHAcm58zeXib3tFojzUpqXXdLs3sEXY/UM9O3Sqg1sztHxjhhcrTBYMCYbHI22QGMCSYYjMHg+H/4+63qNDtrfvN+Pjv13qvX36p69erVqyqNmmEcBzuhfzANhTix4dRbPc83XV/gX8up2D2rZrbWbQ+s7Hi2W+ANpW23KqBLXn29ZTZAlT3/QsMGsaCInmcTa1HpKuSed67e7rl2wzH55VLL8evVCz2v5nQalV6nve6aFX6/nJC9itMiv5Lyrl11ba8G0THPslt2D+J2rXdXx3YvQLhaFLp2u0HhcfNyFKPL50ELCqTZ72PoELm2Wek5LaUmFLPp1n22KFuTQdjeDeIQahaqfJs9hlLT6SpSbkbjQTTecfeG1Gk5rbtt10GFcCqqngjatteg0oZIVByr07RbtIq0zFbX9EAZ667TaYMoVV2zSb3ymuM0bLPVc9q2a/p1pwXhQte2fMcFtUhbolxq1BXsst1o1NseyRUXSpgkNQvHXHu90zDdXttpXFhXIKtoqlWxKzBOrnfct8+zSye8Rt2i4KR3obnmcEZP1VtorKWkp9eG4XjQxKiEuK5tel7PrwFunbMBf3GbygdkxXTP2WzLaHYafl3PQYldRU/WOi6rypbTcDJuoVFfr/nqm0UPtlaUGhy+qDiVdRv8sv4kZVcwC27DJPYxz6n6PYUBbrVmupWMO16pV6u2a+sRnLDPW42Op+15stah7JRn+p3MyKdVKyCuaXSa9Zbj1X02cW07iMZzPZlLntOoc4IF3KxSx2yiNXYVEpmJWCp7YHZBUgRzczYgK2UyKDUdtYrK9aapRrYAD9uog1isj7A6vX4wDLXRsbxc27eUvat1Dk9W6w3ViF9XM1myt7fDftLRcr3VwqL1ambF2USlqLhOO2dl1YF/YAJbld5ao8N+GWumde6wqOSHl+eWWgaLjltfr+uVLjptuCZK2XA2FYEu+LoPHhyh0bPMNp27nHO9quNaauksELQS9iezYB5NxvgmXSBoGdMKc4KWGG79nJ07mdHaG22Fs844msf4xjU5DNGun7cbHgiJHmH50y6GNRnH81lh0jCZkAvWq+7Kpsl4YKCNxKQlzzLVAMpVIFZ6+ouFhFHai958NrkYmsNoZ4wPMjCBVVJXgUs6HT8hDa1sBVOgpOPDUNRsS++ujulSZJiu62wqF+IgSpq17+rUG4g5rrJ2WUNtTCI220SEUq2u2V2b1TJFNdYmk2EYjJ1pmFq23Glpz0Yf8ZmHZQ9aep013zUVbZxXDq8mWo2sNplF903G82CIzxt2lUoFw8EJ1NIyNjoeonddzWj+dTeczSP4LGVOG1WFT9cc33eaoIzmZC8Orb1ZPJlhcip21USsQIWwXMeDi9Zd0NK+YNNnMa/gDGw+qqm2iaEgdljwDfDltooXCyisegPUYhdLYDJrRrMZ0TPfwvpT8ysVgeWIMGG31n1OvlEJ4l29ygwLwRQikbuGVCtRe1K53VqHSGy0bZbS67Iw2pUqipJ9eTqZza/0vpLlwATodOpiIhVs1iuqfZkKanZq3kZwMNmbr8+igQYpa4csmDPvoKH9s5R/0w7m83A2RhW06m3lWwhYKnBJNVl784kbxtF9gM5MpLqjLJP1Q2YUHPpgGHphMigY3PWcJBz4tsl5lRZ8Qs8w9mnsyi2L4bPk282245pqj4YzaxhYaR5mJjoSVUHKNCai6aB/Uc9P1tka4tHdMJvqgcR24NdhXtBaW3kj1I+YTdtKK1mTPXRilugeNXGqm1m6pD7b2Ivn0fbBb/uibVp2DwtUJxf6M09Z21AhBUIkE179brvnO70knMMkYzgvVq62ShY34PG2C1v3mJeBlx1XjXQNARtlyWo4av8v1zmcoABxzGn14NFKTZhVwPT8etNGnAIvmw4Su54ag6FpXVHCVzVusaDLugK7BtUWNKcSlkVotTEIOhdyOdXV5YprckWs+LNgHEd5Rx6AIIlUwu8h8CBcJhuuqNQ9TH3XBimrSPFQGshDkOtVXaeJFariT6kgSgNQuSDToWahIMlizWK749W0LAFbyiUp1nIu0lAruSBDOsbUT8sSpNVckiIdz0Ua6UQuyJBO6o7C1lBKwU4dEqZ4pw9JNeQ1h2QZ6rWqpUSagF5XlKWY1xeFGvJ+RVGGeAPWX93qsQ7c/bGXI4c3W1iWKkm+0Q5iZMB6fpFu9KzOWt1ChSBQykjkUQXW4Fan0yCvP5sMh5Vopn0eGIkT/Za1jb7pdai+xYKZ093DARbYPES9fb6N+KXXlwUE7nKKk+sdBBhpxEj90RjoJSGHE2xVikTKMMR2IcszsSLkDv4YW/hTCvCnrHcUfHwZnDzAH8OFCNq54BL+lHbxp6yQvPlkig/6pIUv5HSiFwMUjGYwn0WXhVwcnTkDXo7O3ITCGJ05i6I0uonC8ugmChdGN1G42A5miJX18SDEd8bOXjQQbgF0NU2OULkfDPdCfCP3VKJ0IwIOrNQKRqGQpe1gFA0PoC9jhmEQBkDmcX8WTefgStTtBrMowCd7o3AW9avRzt4MpkXgTXJ8gSmsq21QOo2KOuuBVs0c/tSbBn04yKFv29jRHcxnsnVI31xL0uKrAFQ5uRxgEQFJM04zisYeiAio5rf4tRVMY6zz/BN4rkqUJYpeyhhtG0kru16CoJdxzJksU8XTBYgw2HWQiwX8dmr3YreQU+EvUitsjCBUfzxlZExOplWHT6t1IJGlqdBYDYO5MvD/yDbyZFQJ62xbqSS9MKy2R3mJvUGpOohyITlxLnr1FtOPJcettFAum1WX9SuVllrGx1qdJru0imORifI4NgQO6URFlydrujyF1JvladNU2dg1li6vdS1VXudp/nq3qw5u9+PCRHmDt6nO5Pe3vE2WN2JyKH+AZTXZ7wd6evP8nVrdo/xB3PZQPthxW+zfQ2gUlA/FzsCpfFjFVxn9w6sNk+N4RHPd5f71SA++hvJR57AZonx0FQkLysfUdPnYmm73cb7mH3+XLp/Q1uUTmbKifFKjukb+yU5blU9xfVU+ta2/P9M+16KdbmogfKA8i5L9vNn1G+RvQUn+VnPN7aK8zVzrkr8dJft9R1fj3NlFh1A+ba2xyfl5OkrqPQMl9Z5pnqtxHM+yNlQq/myrqhbCc6y24k2r41JvDZskeQvBjWWlqvHtKo5jKKsoz6JcR3kzyhqaZXt1lMTfqOnxoLV19qdRczboN0heVN7RqmMLRulstG+/A2V7o30Hce7aaN95BqW70T5zC0qvsdHkd37DsajfwX7Aeek27QpPrJso2Y/zzXNNyi+0GirvuLvVOeejfC6SBfbreSg9lM/vwuAoX9D2fMp7KCm/xz3nkg/cdo3llttZ47z3vWab+gNf9yP0Wyrt3MY0cf52ujjLo9zt6vqoq8d9b/ec8peLXdd3UQ5RnkU58jxEXiHGKMlPUN6McoryFpQvRHkryhnK21DGKG9HOUdJO+2hvBPlvuchZgtxCSXxLqMk3gFK4t2HkngvQkm8F6Mk3ktQEu+lKIn3MpTEe7n0vLMEfIW0uqqHryRByN8lQcxXkSDo75Eg6u+TIOwfkCDuH5Ig8B+RIPKrQaiu/jEJIr+GBJFfS4LIryNB5NeTIPIbSBD5jSSI/CYSRH4zCSK/BYTq81tJEPltJIj8dhJE/hMSRP5TEkR+Bwkiv5MEkf+MBJHfRYLI7wZxM5H/nASR30OCyO8lQeT3kSDyX5Ag8vtJEPkvSRD5AySI/EESRP4QiFuI/GESRP4ICSJ/lASRP0aCyH9FgsgfJ0HkT5Ag8idJEPlTJIj8aRC3EvkzJIj8WRJE/hwJIn+eBJG/QILIXyRB5C+RIPKXSRD5r0kQ+SsgbiPyV0kQ+WskiPx1EkT+Bgkif5MEkb9Fgsh/Q4LIf0uCyH9Hgsh/D+J2In+bBJG/Q4LI/0CCyN8lQeR/JEHk75Eg8vdJEPkHJIj8QxJE/icQdxD5RySI/GMSRP4JCSL/lASR/5kEkX9Ggsg/J0HkfyFB5F+QIPK/glAh6pckiPwrEkT+NxJE/jUJIv+GBJH/nQSR/4MEkf+TBJH/iwSR/1teeZZHajXHdi3OCJmmWAZzymYwnTLJkcb2bDJiWjaf4K+xNpxsCSm3DuZhLEpSXyIIo4RL5V3yY2ZkyL8GwTxQukvIvqIhzm8Wk0ZzcC9OmUIuz9k20rl4NxhMLsUgjd1oZxdH1l2kd0gYB+E8iIagyiG6HDOXQOK4jyNtiEsA0IvzcKSuhHTV0n60hcNZn/SyutnUzSbvAcI49v/bZB+J0SzA2FbEytaMmGO0DO6Y6owwrlF2Pilkn4ZA9mxMmEjOmWeX9qM42kJSJUUZRXIhfVwsxEi4Y3G3XAT2ON6ezEbieWIpUka/LJYV4e8iSR6z58jbgzFkODnUWQPBaS1AWoesE1OzJK4BX7yBPS2OzSY4Z0AFPVmNWQHi+LYyn8XOJrN2nzgx5Viqqka8WJwMR5N7IwsobdziwYhL8hQTxCYMWYEDCGPhYngg4DDbkDaicVgLaRnAG5RUop0QuCVk8OB0WjkWZTKbWnEBySrudTTYan83YOoczmK4mMw49WG9wuaNmLSzH85wXRT6AYyJoCBLQ3WHpK4qujAxrn6H6E2M7UUu7AwPprsx9hW5OMiub2PsKnJJf9ZFgxDBdsvsWja6l0u5sh0Mh1u4BamiIhZb8tguZnkG8Itrk8to4FVSrtYKImEYW7ieGcTiPM4ysyEGYqwl3RHGEtxO5+BdIS9FgzmPXgbrLoAokcgsWCZnxn2coMAtbUezeG6lJkFfF+BGRX5xneMUxmJ/MhoF6EGyPPPzVldo8yGtxKrdxoiUwdDUUfBgsJ94/mIlMxoGN8MJEmOTMkcy9EFTmcwo7SumFc4vTWYX0y6M4djBEI0NVItpR47OI0MTbgExDMnjYixcKb2D0dZkmMDHikG7iFiaTkFiAhg4PnIVefTyKkaDlQjDprBp1DOM5CgKGVIHXN5g7OicAnTD7RDnVgzeWNmOhuE5uDjcMVaVqmUDTdJjagGCIo6f7GobUAl8jExDltMQujCMEEVmB+yDP/H2tnhs3YIaBWIuOV/TyRjTrBta2htvD3kROoZOEXE5ijtpVThAKFnRvbbS75tBjNlLDNVPpRpVTve2hlG8CzC2y976Ez8MRo28d2zEuLKR5HUGfqXi27WiEN+2t+NwjtkszYJBtMdgWM4D3QKKLNAt+oxvyg3r4+0JJkChbQg52Et8CwuhjUA1YUUl3I/66d11er3C/FtdnksLJyJ1RjSUDDcuPJmDL+kP3TTe8QyrP7aszZ7ac+UVjQijTAYpHKY4cc7pLMTA6gNYL9qOsCAwx/hKY74bMZw+h9jRTlaWTwA89qEn6hQtcD2V3mVJ0lmNQS690SrhWgjjSDXLCZspLySCVH+xabY66uyxlHRgDZFpZ8Z4U8+vUNFKNmresOKtWF+m8qYseeeRRwD0GLIvcbaqV3rpw+JRdXM6DREu1CoxtjKxQvkATJmLrNRdWgG2WmVDpYVbCLOLo726vRC4rEteRqW3qe4TDBub9GzuYW+G08bCWI73trdxAwVnVlucQnmKwG1VluzMRCne3+EKaHEzxEyBRbJDJ/w4XBKcszdnYOWug3osPhgOod0Z44JJiiVoVCezfuipxyusqIsxxMtJX7rrCZgw6tVey7aTOzuzsWle8EDIhtpR+JiB6DFnD88KGfAt30DYyBZHabw38rCsYIxYLIhyspSQjsRa6tEVEXx39rASZwm31E9suTzlAsVLyS1iZR3BB5NQShqRGVR64VZqY7Fjli5F+dP/ssAyPrRN4GkBEdlnj3kHpb0geanFhZXrnKPESF7dSzZeqNVxv4zjPW7GQC0kLzWLOiwpvEIs1SE/iUZwp0IATcMvFWByjIxTiDHFlCSf4NUtv8LCN3loTq5V18JdeBjsAzy8yDXUbQyGgHeL3mbNxiKo1RuVnlPFixarcUOGG2794wVpzvpZmwEeA8c75ngHhkI+iShWYI0Irx0zNw14pfZwbycaJ99OFQMroL863UZHL+pOtlWdGw6DvXF/9yofjJBPwq1BwqXV3IAs8QcZ2JnHqDB+ozZFTKkq/WAH83brdBfphVgUhiK08LYp7JnevL5AlAqsVrh9zok+JlTs06I7xgGWzKpYYKlFd+YOu5iQuuJpuIK+qLaHJU1p8dPzjHc5IXXFM/BlthesZIyufGYfYWIO4pgitPBZMV2+i3wVpRY9G4s8y5GPZ4yufM4ArgRHh+9gK5EnCqxWMAP1dsjBodsnc05Xr+UByx4zHeHgTh0RamVrhLiA+tMstagSqghhHQ4n1xyVanWbX9ZjRwcjaF57SKCVqnnzjrYmDHvdEaFWXkeSVnTM64u8VqkVUr77pbSuqsNDgp1ZMN2lk2A2VsQNV4i04kYmTa/JV8T9r5Rp1XNcSXWuFpWNQfHGwxKt1hhFmKVGhAIqD0CRcLq6GatInJwXVsQDi7xWac0RzH3sfhfRNlR+p8hrFWc3+30AJgMQart4oHjQ1eT6kzY4NGTi/DgWDxIPLrBa4S4tsYKpeIh4SMboSlfz6tcPDxMPzTld7bGLCquWdUA8SjzsKmL9gZ/VdNPfKjxGPPyIUCt3KLcQDcT14hEprau6ZAsZ/Q3ikYclWm1z68ofZTxCPOpKmVY9v5+0nRsQhn30UalWv4C4PWyTj8VL5WNyTlffDWVYSoug8Ngir1WeyxWSHJPuEY/LOV39PHp2Cwsb59LHp7Suer4aKiPvK6V4QsrouheEKs+Ncd8nn5jQuqaH6DvAxqR+mgGPEk8QT7pCpBXv0avdSzOWj0n55MMirRewZVMFoBgrUNwmnnJYotW2hlkuEeO2Tj61wGuNvj5scRC4EhVnclbXD9T+id1lSdyUkLoizIOIlaQUZ68QacVtzs96OBmF89kBrgPlzUWB1tnRU5QKqXXLYZHW28XqT34P8QwRZYyuvFfxSfzAGr5Y5LXKUInawYDbMVRGRV6rjLkvIuyrQ90kZXTdVB/gaB3cDYsX5qyun23zAqWJMFyJYhXsEZbjI0KtPJ/piZpUEbWkwH1RxmqFfT3xa+ihNmr6PbQvqY5bkCLUqeUrniMuK+EG7mH4G401cRDrnEj1Mk+j3iLFfVGspW19pCMsUF8EKvugeG588QCPkvtpDQfMk/JLiupdnY5h938pV0zyYGghC5mMG0zaOUC08bJDtej+5fleMCxqvFxdBSUqGHN/FjJU4IRZ1HpFUasGX8AqQqwoqryyqOLMMMcIeRJPCQWxN8QuHw7uDmcTVL2qWNVKnmL1M/AADw5HKxPvEtu4JjpaW8UGwq6LXbxNFKoR4mNxL66TCrIsLx3i1YJuhyF8WspXS0S+5NjLPA4r0cUjxhRnSXUC9bAdzrOK1+QVuduotYjl+VqJAIhkJhgyicBoXycn++riA3uznkQF8vrknqISwvR4HUfLmNU3SN7bIInEpjuZNsJtzF6eHWAtvfGQgstoeoXGm3KNtcl8PhldBeXNV+pcDegtuVJeEzHHwNMyBsP19NYrdXxsPYdV3kZrcYlhhDF8EREnwE7A9fV2qX0b/quvQLB+YTvl+W+TCPBQTWZFXUa8Q+JtJ5f5mADcTLyjIKrklxTvlGGQ/X6kgWsD2BmHj/z3IC08+fRVp73RZDLnjQs+e4+MxrtwK16uDj0dizFd707FngqYecX70gofaywXfzAV2yq85BUfyirU1pVXfDit4L6Riz+Sigv9qfIHIOwG6r8kozirgk3fBV5XppL3ypiUssPnJd6wFHvY774u99LLJJihGJTeL4fYE2GjZA3egycvfAlLOvr82sU1Ahw8CUsfTabUYxuF6fyyxC5bqMoD5RclHr+i+HCM/LgMld1oVDPGcZ4E5J+ApjfZRhqEXiVQEH8S4tZk3JkOsGUnEJ9KugmXg3/0lTZqRRsLvp/LsBtgCJ+RuLCAI+5GwwG6VYn2ERp4nfTZgnO1EfDC2T6u7ImLJj5HoDFmEZXKvFUYOBfxV3Sr4gv0fx0tkous90gMOlYg2VH4KxImUpED3cK3PtRFDQ9zefN+NAqRVsBHv1LUbAZg8F+tqK9KMGlNYTF8TQ5CbFhjxeP0gglDkoIPvlG4ANK5G3K5b8qr+txapgm/+5YMkpP41yTe/WCtw1tXQ+VA3cQxFrCTjTFSbBtg1eA+IvE4ONlXHUnDsqp4n8RjYVLBU/gcwKkCpurbaV3enXo+ZrzM4mHxiIaZ34J9SOLBUW0JSd9W8e44h3t1MLmNQ71ewkOkPvhzRLCV/B5e33YQ7AbO2PGr+qc1sZjK72fy7e1DFT8oTKC3O9kbDrwR9hJTPQbRTX8oY+YTOrt4Fh4zFZufKpK0CXP4I12Fzql8Pa/4sa7YVM8UFfETzepUG/xPlTkQVNQtjIsn0Klea5hd3iP8LOVVvPk5HDiJxlRfxbNoFFtn0dNfpHrhoJsYaBVPpNpAnKjsuuRbUv4SMOg+3HLm7U25lJMoxchkcrtk4GX+8Cvd3STLwnrkoCp4YM0A4gTh/wD4tdyF26h3HTgO3mFrGWskLzuyG4WXCIFL5H4w3g9ihjPsfXANPJIIOcXqH2J970MPkIbiKyEnjmf5kv5oHQkDTFRWvy8nlP6J+eOE1PUKtDHpw2VhHNxPF8QeIpbyUL49nb8S0RpG/Yt44wW3hN7g+MnAangqSGTOL40xchDoJ9EDzqYjsOHPop0dBNSBs4+hc2WXJppKWpC7k3k8ncwT1ogvBdOELnXg+OnN1alDP2DEFDCWqdBijJFgw5Z4sNCZThkuvBPqILdAwykDfwdXUCNln+/i0ilOR433oeXJFhra5/QuyZVByFjY0pjHsCfD4ZQVYjz6S7x+coDpyGM8+0vcJB0eZIzVIk+gqRl6uypOIsnEbUKiU9PjxfhOecAO13ntcddeiHMPbzixBtGRVmJO5CtYOrhbpUCbIm6G82BAbzbkFm5e4b7hkMubFodpmrAThp8+J+Nmsmg5Ax6tiNI4R0QMlGV2N+V/jEdPhS325WKMABAME4MsBf0+4ERZLMeMv16oTseoWUl5n83eIY6lvIXlAhsq8dPE6hTGQNhG5D2uyKTnXT4dg8VaUuEAZtMNt4OD4SQYQHAqPmSvCB39qZSnCwPJTPMz3Jz9L+8BAABdkUtME1EUhv8zc6cwUloVxGhURg31DdEE3UjroxsXCFEjiYkLH5OmVko0BdwM9IFVd+4MJiiaaHRjjenSgHHhwrrFGHfgzgTCkg2Pc25hmjCZO/eb85/7n3PvJTJgIvjtfXFZhc5cTVxJDvVePH0vdcPt7umL93QmUt1QJgEGFFnxgTuD/W46gwDVjwKwsRXbAYJ2wX4ow+q9lXCdk7WMoEz86ClMsqBJ+NTIr0plY0hgmI2Wg0sRsSK2arTmsm/Ypw7rTg1jwGT+5fjHqmUR+KRdnxH6GhHS1s3YkedQC3ZiV45htyTsUXuNfWiFwx0eMA+iTUWIYHi/Z2a8udlZb2F+XtJM+fAuCYdwuAA4dOT8kJtOPnQuu48yiLv9SefCwP27qEYleEKCOnaUpFu10aLFBfL/Iw+MHLIdZlJdDylxrJPmLN4Uv9yBTjGh1qMj5YkO1Ns2UbXC5rowRtu/3DSbtzil0rbbl1q8tyt/SscWx+2zE2kF67MNHEc7n0mWkOP6hAJhjPCYUCQ8ITwlOawXhEnCK1rlJ8xjNfyOb/AnocLXGKBp/kl9LUev/bNixocfDTEfpl//jRoi+TA81RrVkg/Pvw92acmHtgBNMWRqoKWmwrkuH/RykXzQJUTyQbchkg9erFOgXAORgDU=(/figma)--><sup><span>‡</span></sup>Based on performance testing measuring magnetic field expressed in tesla (T) on the applicator surface (1.35 T for CoolTone vs 0.9 T for competitor device).</p>
Before CoolTone treatment.
Image Disclaimer:<p>Patient was treated with CoolTone™ on her abdomen. Results may vary.</p>
2
HeadlineItem:Unique offerings.
summary:<p>Allergan delivers a one-of-a-kind of provider partnership. The benefits will extend far beyond just the systems themselves to include amazing support, programs, and trainings designed to help you as you grow your CoolSculpting and CoolTone business.</p> <p>From loyalty programs to co-op advertising reimbursement, you’ll find incredible offerings you won’t find anywhere else.</p>
ctaLabel:Learn More
ctaLink:/training-programs/
Summary Disclaimer:
Before CoolTone treatment.
Image Disclaimer:<p style="text-align: right;">Models. Not patients.</p>

Hello Opportunity.

Take Your Practice Further with THE Allergan Body Contouring portfolio. From the leading company in medical aesthetics.¹

INDICATIONS & IMPORTANT SAFETY INFO FOR COOLSCULPTING & COOLTONE
CoolSculpting® Indications

The CoolSculpting® procedure is FDA-cleared for the treatment of visible fat bulges in the thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm in patients with a Body Mass Index (BMI) of ≤ 30 and in submental and submandibular areas in patients with a BMI of ≤ 46.2. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments.

CoolSculpting® Important Safety Information

CoolSculpting® is contraindicated in patients with cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.

Ask your patient about any medical conditions including recent surgery, pre-existing hernia, and any known sensitivities or allergies.

During the procedure patients may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, and cramping at the treatment site. These sensations subside as the area becomes numb. Following the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, tingling, stinging, tenderness, cramping, aching, itching, or skin sensitivity, and sensation of fullness in the back of the throat after submental or submandibular area treatment.

Rare side effects may also occur. Paradoxical hyperplasia (visibly enlarged tissue volume in the treated area) may develop 2-5 months after treatment and requires surgical intervention for correction.

As with any medical procedure, a consultation should be done by a licensed healthcare professional to determine if the patient is a candidate for treatment. Consult the CoolSculpting® System User Manual for a complete list of Contraindications, Warnings, Precautions, and potential side effects. Treatment applications that deviate from the guidelines are not recommended.

CoolTone Indications

The CoolTone™ device is indicated for improvement of abdominal tone, strengthening of the abdominal muscles, and development for firmer abdomen. CoolTone™ is also indicated for strengthening, toning, and firming of buttocks and thighs.

CoolTone Important Safety Information

CoolTone treatment is contraindicated in placing the active applicator over metal, electrical, or electronic implants/devices in the treatment area like cardiac pacemakers, cochlear implants, intrathecal pumps, implanted defibrillators, implanted neurostimulators, drug pumps, or hearing aids.

CoolTone is also contraindicated in placing the active applicator over menstruating uterus, over areas of the skin that lack normal sensation, and in patients with fever, malignant tumor, hemorrhagic conditions, epilepsy, recent surgical procedure, pulmonary insufficiency, or pregnancy.

CoolTone should be used with caution in patients with Graves’ disease, active bleeding disorders, or seizure disorders.

Women who are close to menstruation may find that it comes sooner, or cramping is increased or intensified with CoolTone treatments, therefore, it is recommended to not undergo treatment during this time of the month.

CoolTone should not be used in the heart or head areas, areas of growth plate, over the carotid sinus nerves, or over the neck or mouth. CoolTone™ should not be applied over swollen, infected, inflamed areas or skin eruptions. Caution should be used for patients with suspected or diagnosed heart problems.

Ensure that persons with pacemakers are not present in vicinity of the device during treatment.

Common adverse effects may include, but may not be limited to muscular pain, temporary muscle spasm, temporary joint or tendon pain, and local erythema or skin redness.

Consult the CoolTone User Manual for a complete list of Contraindications, Warnings, Precautions, and potential side effects. Treatment applications that deviate from the guidelines are not recommended.

References: 1. Medical insight, May, 2019. 2. Data on file, Allergan; Aesthetic foundational sizing & Allergan category opportunity.

INDICATIONS & IMPORTANT SAFETY INFO FOR COOLSCULPTING & COOLTONE
CoolSculpting® Indications

The CoolSculpting® procedure is FDA-cleared for the treatment of visible fat bulges in the thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm in patients with a Body Mass Index (BMI) of ≤ 30 and in submental and submandibular areas in patients with a BMI of ≤ 46.2. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments.

CoolSculpting® Important Safety Information

CoolSculpting® is contraindicated in patients with cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.

CoolTone Indications

The CoolTone™ device is indicated for improvement of abdominal tone, strengthening of the abdominal muscles, and development for firmer abdomen. CoolTone™ is also indicated for strengthening, toning, and firming of buttocks and thighs.

CoolTone Important Safety Information

CoolTone treatment is contraindicated in placing the active applicator over metal, electrical, or electronic implants/devices in the treatment area like cardiac pacemakers, cochlear implants, intrathecal pumps, implanted defibrillators, implanted neurostimulators, drug pumps, or hearing aids.

INDICATIONS & IMPORTANT SAFETY INFO FOR COOLSCULPTING & COOLTONE